INGELHEIM, Germany & COPENHAGEN, Denmark–(BUSINESS WIRE)–Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with su…
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1
INGELHEIM, Germany & COPENHAGEN, Denmark–(BUSINESS WIRE)–Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with su…